BOLT – bolt biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 [Yahoo! Finance]
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its price target lowered by analysts at Stifel Nicolaus from $1.50 to $1.25. They now have a "hold" rating on the stock.
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Form S-8 Bolt Biotherapeutics,
Form 10-K Bolt Biotherapeutics, For: Dec 31
Form 8-K Bolt Biotherapeutics, For: Mar 24
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.